علاج الورم اللمفاوي للخلايا التائية الشبيه بالتهاب الشحم تحت الجلد بدون HLH وعبء ورمي منخفض

References

• SPTCL Without HLH and Low Tumor Burden (Localized or Limited Subcutaneous Disease)
• While chemotherapy may be considered for patients presenting with HLH, immunomodulatory therapies are considered for patients who present without HLH.
• Single agents (CsA, methotrexate, or bexarotene), with or without prednisone, can be considered as options for first-line therapy.
• ISRT can be considered as a local therapy for single lesion or limited disease with and without symptoms of HLH.
• Depending on the response to first-line therapy (CR or PR), options such as observation or single-agent maintenance therapy are recommended.